Circular RNA

But then Thomas joined together with one of the people from his lab.

And we basically started in 2022 with the aim initially to build an oncolytic adenovirus platform expressing circRNA, which then subsequently evolved into what we're doing now, which is the gene therapy in vivoCAR.

That's how we ended up moving into the space.

Oh, nice.

So this is irreversible and potentially toxic.

But it's the only tool available if you want to use this kind of in vivo approach for cancer patients at the moment.

Now, with our gene expression system using circRNA, we can get expression for three to six months on a single dose.

So that's positioned this technology right in the middle.